CUE

Cue Biopharma, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $25.25
52-Week Range: $4.98 – $45.50
Market Cap: $185.75M
P/E (TTM): —
EPS (TTM): -29.59
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 57.85
PEG Ratio: —
Return on Equity: -1603.48%
Return on Assets: -172.66%
Gross Margin: -99.15%
Operating Margin: -1113.31%
Profit Margin: 0.00%
Current Ratio: 1.25
Debt/Equity: 1.33
Total Debt: $3.08M
Free Cash Flow: $-33.43M
Revenue Growth: 166.70%
Earnings Growth: —
Enterprise Value: $171.41M

CUE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.25M	$5.49M	$9.29M	$27.47M
Research & Development	$38.58M	$40.80M	$36.30M	$37.74M
Selling, General & Admin	$16.17M	$16.68M	$14.59M	$16.24M
Operating Expenses	$54.75M	$57.48M	$50.88M	$53.99M
Operating Income	-$53.50M	-$51.99M	-$41.59M	-$26.52M
EBITDA	-$50.49M	-$46.05M	-$37.53M	-$22.27M
Pretax Income	-$53.01M	-$50.73M	-$40.67M	-$26.10M
Income Tax	$0.00	—	$0.00	$500.00K
Net Income	-$53.01M	-$50.73M	-$40.67M	-$26.60M
Diluted EPS	-44.70	-33.30	-21.60	-8.40
Diluted Shares	1.19M	1.53M	1.88M	3.16M

CUE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$51.61M	$48.51M	$22.46M	$27.14M
Receivables	$57.00K	$1.70M	$945.00K	$7.45M
Current Assets	$77.19M	$51.45M	$25.14M	$36.98M
Total Assets	$91.28M	$61.53M	$32.19M	$42.21M
Current Liabilities	$11.55M	$17.08M	$13.69M	$13.49M
Long-Term Debt	$8.04M	$4.20M	—	—
Total Debt	$19.32M	$14.70M	$8.88M	$4.20M
Total Liabilities	$25.60M	$24.45M	$14.69M	$15.78M
Retained Earnings	-$250.46M	-$301.19M	-$341.86M	-$368.47M
Shareholders' Equity	$65.68M	$37.09M	$17.50M	$26.43M
Working Capital	$65.64M	$34.37M	$11.45M	$23.49M

CUE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$41.81M	-$39.96M	-$36.33M	-$21.69M
Capital Expenditure	-$171.00K	—	-$66.00K	-$177.00K
Free Cash Flow	-$41.98M	-$39.96M	-$36.40M	-$21.86M
Depreciation & Amortisation	$1.81M	$3.44M	$2.35M	$3.48M
Stock-Based Compensation	$9.50M	$8.18M	$6.85M	$4.74M
Investing Cash Flow	-$24.61M	$25.00M	$32.00K	$75.00K
Financing Cash Flow	$53.66M	$11.86M	$10.24M	$26.29M
Net Change in Cash	-$12.76M	-$3.10M	-$26.05M	$4.68M

CUE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$421.00K	$2.95M	$2.15M	$21.94M	$5.69M	$7.88M
Research & Development	$8.55M	$7.91M	$4.75M	$16.53M	$6.90M	$49.01M
Selling, General & Admin	$4.17M	$3.68M	$4.94M	$3.45M	$4.15M	$46.56M
Operating Expenses	$12.72M	$11.59M	$9.69M	$19.98M	$11.05M	$95.57M
Operating Income	-$12.30M	-$8.63M	-$7.54M	$1.96M	-$5.36M	-$87.69M
EBITDA	-$11.25M	-$7.64M	-$6.78M	$3.34M	-$4.25M	-$152.65M
Pretax Income	-$12.26M	-$8.48M	-$7.45M	$2.08M	-$5.18M	-$153.07M
Net Income	-$12.26M	-$8.48M	-$7.45M	$1.58M	-$5.18M	-$153.07M
Diluted EPS	-4.95	-2.70	-2.10	0.30	-1.08	-24.14
Diluted Shares	2.48M	3.18M	3.36M	3.68M	4.81M	6.34M

CUE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$13.14M	$27.49M	$11.70M	$27.14M	$16.38M	$17.39M
Receivables	$0.00	$532.00K	$2.29M	$7.45M	$7.25M	$7.28M
Current Assets	$15.93M	$30.84M	$25.82M	$36.98M	$26.39M	$26.62M
Total Assets	$22.25M	$40.71M	$31.64M	$42.21M	$30.88M	$30.71M
Current Liabilities	$15.50M	$19.25M	$15.52M	$13.49M	$7.39M	$21.22M
Total Debt	$7.13M	$7.63M	$6.17M	$4.20M	$3.44M	$3.08M
Total Liabilities	$15.67M	$22.55M	$18.40M	$15.78M	$9.27M	$28.40M
Retained Earnings	-$354.12M	-$362.60M	-$370.05M	-$368.47M	-$373.64M	-$526.71M
Shareholders' Equity	$6.58M	$18.16M	$13.25M	$26.43M	$21.61M	$2.31M
Working Capital	$433.00K	$11.59M	$10.29M	$23.49M	$19.00M	$5.41M

CUE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$8.17M	-$3.42M	-$9.02M	-$1.08M	-$10.94M	-$29.00M
Capital Expenditure	-$150.00K	-$27.00K	—	—	-$121.00K	—
Free Cash Flow	-$8.32M	-$3.44M	-$9.02M	-$1.08M	-$11.06M	-$29.00M
Depreciation & Amortisation	$882.00K	$796.00K	$596.00K	$1.21M	$929.00K	$408.00K
Stock-Based Compensation	$1.34M	$1.26M	$1.53M	$610.00K	$48.00K	$23.84M
Investing Cash Flow	-$150.00K	-$27.00K	-$6.77M	$7.02M	-$121.00K	$0.00
Financing Cash Flow	-$1.00M	$17.80M	$1.00K	$9.49M	$306.00K	$30.02M
Net Change in Cash	-$9.32M	$14.36M	-$15.79M	$15.44M	-$10.76M	$1.01M

Market Snapshot

About

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively modulate disease-relevant T cells. Headquartered in Boston, Massachusetts, the company's Immuno-STAT platform is designed to harness the body's immune system to fight cancer and autoimmune diseases. Cue Biopharma's lead programs target various cancers including HPV-driven malignancies and other solid tumors. The company's approach aims to deliver more targeted immunotherapy with improved efficacy and reduced side effects compared to traditional treatments.